The ongoing COVID pandemic is having an impact on all aspects of the US Food & Drug Administration’s operations, but (apart from inspections) the effects may be most dramatic in the agency’s use of public advisory committees.
The disruptions and logistical complications for “virtual” advisory committee meetings are no doubt contributing to record-low numbers of review. In...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?